Extra Medullary Relapse post Allogenic Stem Cell Transplantation Tends to Occur Late, Patients have a Better Chance of Receiving a Second Transplant with Better Outcomes
Acute myeloid leukemia (AML) relapse after Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT) remains a significant cause of mortality and morbidity. Bone marrow Relapse is the most frequent presentation. Extra Medullary Relapse (EMR) is less common, the incidence of EMR in the literature ranges from 0.65% up to 41%.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Mona Hassanein, Ghada Elgohary, Noura Alhashim, Maamoun Alsermani, Muhned Alhumaid, Syed Osman Ahmed, Feras Alfraih, Mahmoud Aljurf, Fahad Almohareb, Fahad Alsharif, Hazzaa Alzahrani, Naeem Chaudhri, Amr Hanbali, Shahrukh Hashmi, Mohamed Said, Waleed Rash Tags: Acute Myeloid Leukemia Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Leukemia | Lymphoma | Myeloma | Stem Cell Therapy | Stem Cells | Transplants